High FOXM1 levels are generally associated with therapeutic resistance of cancer cells and poor prognosis of cancer patients due to decreased efficacy of the traditionally used therapeutic strategies [1–3, 5, 13, 14], it shows that FOXM1 may serve as a selective target in human solid cancers. This evidence concerns the gene FOXM1 and cancer.